Update on the Pharmacological Actions of Enoxaparin in Nonsurgical Patients
Egidio Imbalzano,
Luana Orlando,
Giuseppe Dattilo,
Marianna Gigliotti De Fazio,
Giuseppe Camporese,
Vincenzo Russo,
Alessandro Perrella,
Francesca Futura Bernardi,
Pierpaolo Di Micco
Affiliations
Egidio Imbalzano
Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy
Luana Orlando
Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy
Giuseppe Dattilo
Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy
Marianna Gigliotti De Fazio
Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy
Giuseppe Camporese
General Medicine Department, Thrombotic and Haemorrhagic Disorders Unit, Department of Internal Medicine, University Hospital of Padua, 35131 Padua, Italy
Vincenzo Russo
Department of Translational Science, University Vanvitelly, 81025 Caserta, Italy
Alessandro Perrella
Unit Emerging Infectious Disease, Ospedali dei Colli, P.O. D. Cotugno, 80131 Naples, Italy
Francesca Futura Bernardi
Department of Experimental Medicine, Università degli Studi della Campania Luigi Vanvitelli, 80100 Naples, Italy
Pierpaolo Di Micco
AFO Medicina, P.O. Santa Maria delle Grazie, ASL Napoli 2 Nord, 80078 Pozzuoli, Italy
Low-molecular-weight heparins are a class of drugs derived from the enzymatic depolymerization of unfractionated heparin that includes enoxaparin. Several studies have been performed on enoxaparin in recent years, in particular for the prevention and treatment of venous thromboembolism and for the treatment of acute coronary syndrome. Furthermore, the use of enoxaparin has been extended to other clinical situations that require antithrombotic pharmacological prevention, such as hemodialysis and recurrent abortion. In this review, we report the main clinical experiences of using enoxaparin in the prevention of VTE in nonsurgical patients.
